[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-219743-105":3,"detail-sidebar-cat-1-en-105":80,"doc-detail-219743-en":126},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","adverse-effects-and-safety-of-etirinotecan-pegol-a-systematic-review-in-cancer-treatment","Adverse Effects and Safety of Etirinotecan Pegol - A Systematic Review in Cancer Treatment","","Cancer prevalence continues to rise while existing therapies may be insufficient, driving development of antitumor drugs with improved efficacy and reduced adverse effects. Polyethylene glycol (PEG) conjugation is highlighted as a technology to enhance chemotherapy safety and performance. Etirinotecan Pegol (EP/NKTR-102), the PEGylated form of irinotecan, inhibits topoisomerase I to promote cancer cell apoptosis. This systematic review evaluates EP anti-tumor evidence across cancers using Scopus and clinicaltrials.gov, excluding non-English, duplicates, and data-missing studies.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/adverse-effects-and-safety-of-etirinotecan-pegol-a-systematic-review-in-cancer-treatment/219743/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/adverse-effects-and-safety-of-etirinotecan-pegol-a-systematic-review-in-cancer-treatment/219743.png","ImageObject",442,249,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-09-24","2026-09-08",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is Etirinotecan Pegol (EP) and how does it work?","Question",{"text":62,"@type":63},"Etirinotecan Pegol (EP), also known as NKTR-102, is the PEGylated form of irinotecan. It induces cancer cell apoptosis by inhibiting topoisomerase I.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"Which databases and search terms were used in the systematic review?",{"text":67,"@type":63},"Studies were identified using the Scopus database, using search terms Etirinotecan Pegol and NKTR-102. Ongoing studies were also identified from clinicaltrials.gov.",{"name":69,"@type":60,"acceptedAnswer":70},"What studies were excluded during the review process?",{"text":71,"@type":63},"The review excluded studies published in languages other than English, duplicate articles, and studies with no data.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},219743,1788889343,{"code":4,"msg":81,"data":82},"success",[83,88,93,98,103,108,113,118,123],{"id":84,"doc_module":22,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},11,"Presentations",90,"presentations",{"id":89,"doc_module":22,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},12,"Resumes",80,"resumes",{"id":94,"doc_module":22,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},14,"Invoices",70,"invoices",{"id":99,"doc_module":22,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},15,"Posters",60,"posters",{"id":104,"doc_module":22,"doc_module_name":25,"category_name":105,"show_sort_weight":106,"slug":107},16,"Social Media",50,"social-media",{"id":109,"doc_module":22,"doc_module_name":25,"category_name":110,"show_sort_weight":111,"slug":112},17,"Forms",40,"forms",{"id":114,"doc_module":22,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},18,"Letters",30,"letters",{"id":119,"doc_module":22,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},21,"Paper Templates",5,"papers-templates",{"id":124,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":125},158,"general-158",{"code":4,"msg":81,"data":127},{"doc_id":78,"user_id":128,"nickname":42,"user_avatar":129,"doc_module":22,"category_id":124,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":135,"language":136,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":12,"update_tm":79,"read_time":140},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, In Cancer Treatment: A Systematic Review\nMohamad Samare-Najaf 1,2, Ali Samareh 3, Navid Jamali 1,2, Ali Abbasi 1, Cain C. T. Clark 4, Majid Jafari Khorchani 1, Fatemeh Zal 1,5,*\n1 Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.\n2 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran\n3 Department of Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.\n4 Centre for Intelligent Healthcare, Coventry University, CV1 5FB, U.K.\n5 Infertility Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran.\n*Corresponding author:\nFatemeh Zal Ph.D.\nDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.\nInfertility Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran.\nE-mail address:fatemehzal@yahoo.com\nTel/Fax: +98 7132303029\nAbstract\nDue to the increasing prevalence of cancer, and the inadequacy of current therapies, the development of novel antitumor pharmaceutics, with higher efficacies and lower adverse effects, is considered a fundamental tenet of contemporary cancer management. Poly-Ethylene-Glycol (PEG) attachment is a novel pharmaceutical technology to improve the efficacy and safety of chemotherapies. Etirinotecan Pegol (EP), also known as NKTR-102, is the PEGylated form of Irinotecan (CPT-11), which causes cancer cell apoptosis by inhibiting the topoisomerase I enzyme. The present study reviews and evaluates various reports of the EP anti-tumor activity in various cancers. Studies were identified using the Scopus database, with no exclusions. The search terms included Etirinotecan Pegol and NKTR-102, which yielded 125 articles (66 and 59 articles, respectively). In addition, the clinicaltrials.gov web site was used to find ongoing studies, which resulted in the addition of two studies. Subsequently, we excluded studies that were published in languages other than English, duplicate articles, and studies with no data. This systematic review clarifies that EP possesses numerous advantages over many other medications, such as safety, efficacy, increased half-life, increased health-related quality of life, increased overall survival, increased progression-free survival, and decreasing the adverse events in the treatment of various cancers.\nKeywords Cancer; Chemotherapy; Drug Safety; Toxicology; Clinical Trials, Topoisomerase Inhibitors.\n1. Introduction\nThe World Health Organization (WHO) estimates that cancer is one of the most prevalent causes of, worldwide \u0013 ADDIN EN.CITE \u003CEndNote>\u003CCite>\u003CAuthor>Siegel\u003C/Author>\u003CYear>2017\u003C/Year>\u003CRecNum>16\u003C/RecNum>\u003CDisplayText>(1)\u003C/DisplayText>\u003Crecord>\u003Crec-number>16\u003C/rec-number>\u003Cforeign-keys>\u003Ckey app=\"EN\" db-id=\"seswpe00utfsapevpf65dwfv9edtr2wwsfwp\" timestamp=\"1539798376\">16\u003C/key>\u003C/foreign-keys>\u003Cref-type name=\"Journal Article\">17\u003C/ref-type>\u003Ccontributors>\u003Cauthors>\u003Cauthor>Siegel, Rebecca L\u003C/author>\u003Cauthor>Miller, Kimberly D\u003C/author>\u003Cauthor>Jemal, Ahmedin\u003C/author>\u003C/authors>\u003C/contributors>\u003Ctitles>\u003Ctitle>Cancer statistics, 2017\u003C/title>\u003Csecondary-title>CA: a cancer journal for clinicians\u003C/secondary-title>\u003C/titles>\u003Cperiodical>\u003Cfull-title>CA: a cancer journal for clinicians\u003C/full-title>\u003C/periodical>\u003Cpages>7-30\u003C/pages>\u003Cvolume>67\u003C/volume>\u003Cnumber>1\u003C/number>\u003Cdates>\u003Cyear>2017\u003C/year>\u003C/dates>\u003Cisbn>1542-4863\u003C/isbn>\u003Curls>\u003C/urls>\u003C/record>\u003C/Cite>\u003C/EndNote>\u0014(1)\u0015. Indeed, the incidence and mortality of this disease is growing \u0013 ADDIN EN.CITE \u003CEndNote>\u003CCite>\u003CAuthor>Uzunalli\u003C/Author>\u003CYear>2019\u003C/Year>\u003CRecNum>104\u003C/RecNum>\u003CDisplayText>(2)\u003C/DisplayText>\u003Crecord>\u003Crec-number>104\u003C/rec-number>\u003Cforeign-keys>\u003Ckey app=\"EN\" db-id=\"seswpe00utfsapevpf65dwfv9edtr2wwsfwp\" timestamp=\"1607326937\">104\u003C/key>\u003C/foreign-keys>\u003Cref-type name=\"Journal Article\">17\u003C/ref-type>\u003Ccontributors>\u003Cauthors>\u003Cauthor>Uzunalli, Gozde\u003C/author>\u003Cauthor>Dieterly, Alexandra M\u003C/author>\u003Cauthor>Kemet, Chinyere M\u003C","cbCaiutKxOk6DG3s","https://ap.wps.com/l/cbCaiutKxOk6DG3s","docx",79700,22,"English","# Abstract\n# Keywords\n# Introduction\n## Cancer epidemiology and unmet therapeutic needs\n## PEGylation and mechanism of Etirinotecan Pegol","[{\"question\":\"What is Etirinotecan Pegol (EP) and how does it work?\",\"answer\":\"Etirinotecan Pegol (EP), also known as NKTR-102, is the PEGylated form of irinotecan. It induces cancer cell apoptosis by inhibiting topoisomerase I.\"},{\"question\":\"Which databases and search terms were used in the systematic review?\",\"answer\":\"Studies were identified using the Scopus database, using search terms Etirinotecan Pegol and NKTR-102. Ongoing studies were also identified from clinicaltrials.gov.\"},{\"question\":\"What studies were excluded during the review process?\",\"answer\":\"The review excluded studies published in languages other than English, duplicate articles, and studies with no data.\"}]","Adverse Effects and Safety of Etirinotecan Pegol - A Systematic Review in Cancer Treatment | DOCX",8]